FORT LAUDERDALE, FL / ACCESSWIRE / November 22, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of th ...

Opens in a new tab or window The FDA declined to grant full approval to obeticholic acid (Ocaliva) for treating primary ...

Semaglutide (Wegovy) improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) and led ...

Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy, today announced that it has received approval of clinical trial application (CTA ...

In the wake of an unfavorable advisory committee meeting in September, Intercept Pharmaceuticals’ bid to win full approval ...

Not only is Wegovy extremely effective (people lose about 15% of their body weight in a year), it also appears to have many ...

It is this fibrosis that leads to cirrhosis of the liver, and anywhere between 12-20 per cent of people with type 2 diabetes ... Some newer antidiabetic drugs may help, including SGLT-2 inhibitors and ...

The FDA informed Intercept that it is unable to approve the sNDA in its current form, consistent with the outcome of the Gastrointestinal Drugs Advisory Committee (GIDAC) meeting in September 2024. In ...